Results 41 to 50 of about 14,491 (226)

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)

Frontiers in Oncology, 2023
BackgroundAlectinib is first-line therapy in patients with stage IV non-small cell lung carcinoma (NSCLC) and an anaplastic lymphoma kinase (ALK) fusion.
Marinda Meertens, M. Benthe Muntinghe-Wagenaar, Barend J. Sikkema, Marta Lopez-Yurda, Valesca P. Retèl, Marthe S. Paats, Rob Ter Heine, Ed Schuuring, Wim Timens, Daan J. Touw, Job F. M. van Boven, Adrianus. J. de Langen, Sayed M. S. Hashemi, Lizza E. L. Hendriks, Sander Croes, Michel M. van den Heuvel, Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Egbert F. Smit, Alwin D. R. Huitema, Alwin D. R. Huitema, Alwin D. R. Huitema, Neeltje Steeghs, Anthonie J. van der Wekken   +23 more
doaj   +1 more source

Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma. [PDF]

, 2017
The advent of genomics has led to the identification of specific "driver" mutations in oncogenic kinases, and the development of targeted small molecule inhibitors to block their tumor-driving functions.
Bivona, Trever G, Neel, Dana S
core   +1 more source

Mechanistic insight into RET kinase inhibitors targeting the DFG-out conformation in RET-rearranged cancer [PDF]

, 2017
Oncogenic fusion events have been identified in a broad range of tumors. Among them, RET rearrangements represent distinct and potentially druggable targets that are recurrently found in lung adenocarcinomas.
Andreas H. Scheel, André Richters, Borrello, Carina Lorenz, Daniel Schütte, Dennis Plenker, Florian Mrugalla, Frauke Leenders, Frett, Gautschi, Georg Pall, Gozgit, Heil, Joachim Diebold, Johannes Brägelmann, Johannes M. Heuckmann, Julian Engel, Justina Stark, Jürgen Wolf, Kevan M. Shokat, Kris Gevaert, Maarten Aerts, Marcel A. Dammert, Marina Keul, Martin L. Sos, Martin Peifer, Maximilian Riedel, Mike Bührmann, Mrugalla, Neil Q. McDonald, Oliver Gautschi, Oliver Pagel, Phillip P. Knowles, Rakhee Chauhan, Reinhard Buettner, René P. Zahedi, Roman K. Thomas, Sigalov, Song, Stefan M. Kast, Verena Tischler, Yang, Yannic Alber, Yanrui Song, Yoh   +44 more
core   +1 more source

Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis

Biomolecules & Biomedicine, 2021
Most advanced non-small cell lung cancer (NSCLC) patients are accompanied by brain metastasis which is the major cause of increased mortality. The fusion rearrangement of anaplastic lymphoma kinase (ALK) gene is an important feature of brain metastasis ...
Xu Feng, En-Shi Xu
doaj   +1 more source

First-Line Treatment of ALK-Positive NSCLC

healthbook TIMES. Oncology Hematology, 2019
Non-small cell lung cancer (NSCLC) patients with rearrangements in the anaplastic lymphocyte kinase (ALK) gene are highly sensitive to ALK tyrosine kinase inhibitors (TKIs) like alectinib. Here, the case of a 77-year-old male patient with newly diagnosed
Hasna Bouchaab
doaj   +2 more sources

Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome [PDF]

, 2017
Background: Neuroblastoma is an aggressive childhood malignancy of the sympathetic nervous system. Despite multi-modal therapy, survival of high-risk patients remains disappointingly low, underscoring the need for novel treatment strategies.
Cannoodt, Robrecht, Claeys, Shana, De Preter, Katleen, Denecker, Geertrui, Durinck, Kaat, Kumps, Candy, Speleman, Franki   +6 more
core   +3 more sources

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial

Thoracic Cancer, 2021
Background The efficacy of crizotinib treatment for recurring EML4‐ALK‐positive non‐small cell lung cancer (NSCLC) previously treated with alectinib is unclear.
Daijiro Harada, Hideko Isozaki, Toshiyuki Kozuki, Toshihide Yokoyama, Hiroshige Yoshioka, Akihiro Bessho, Shinobu Hosokawa, Ichiro Takata, Nagio Takigawa, Katsuyuki Hotta, Katsuyuki Kiura, Okayama Lung Cancer Study Group   +11 more
doaj   +1 more source

Two Uncomplicated Pregnancies on Alectinib in a Woman With Metastatic ALK-Rearranged NSCLC: A Case Report

JTO Clinical and Research Reports, 2022
Lung cancer incidence is increasing in pregnancy due in part to advanced maternal age. A subset of patients with NSCLC during pregnancy harbor an ALK gene rearrangement.
Chloe Weidenbaum, DO, Christopher G. Cann, MD, Sarah Osmundson, MD, MS, Wade T. Iams, MD, MSCI, Travis Osterman, DO, MS   +4 more
doaj   +1 more source

Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs [PDF]

, 2016
fusion between the EML4 (echinoderm microtubule-associated protein-like) and ALK (anaplastic lymphoma kinase) genes was identified in non-small cell lung cancer (NSCLC) in 2007 and there has been rapid progress in applying this knowledge to the benefit ...
Bayliss, R, Choi, J, Fennell, DA, Fry, AM, Richards, MW   +4 more
core   +2 more sources

Analysis of Baseline Molecular Factors Associated With the Risk of Central Nervous System Progression Among Alectinib-Treated Patients With ALK–Positive NSCLC

JTO Clinical and Research Reports
Introduction: Despite receiving alectinib therapy, patients with ALK-positive NSCLC remain at risk of central nervous system (CNS) progression. Our retrospective study aimed to identify baseline clinical and molecular factors associated with the risk of ...
Lianxi Song, MD, Huan Yan, MD, Qinqin Xu, MD, Chunhua Zhou, MD, Juan Liang, MD, Shaoding Lin, MD, Ruiguang Zhang, MD, Juan Yu, MD, Yang Xia, MD, Nong Yang, MD, Liang Zeng, MD, Yongchang Zhang, MD   +11 more
doaj   +1 more source